Scott A. Biller
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Biochemical and Molecular Research, Cancer, Hypoxia, and Metabolism, Epigenetics and DNA Methylation, Plant biochemistry and biosynthesis
Most-Cited Works
- → An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells(2013)1,144 cited
- → Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation(2013)791 cited
- → Electrophilic properties of itaconate and derivatives regulate the IκBζ–ATF3 inflammatory axis(2018)705 cited
- → Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2005)619 cited
- → Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes(2008)617 cited
- → AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations(2017)450 cited
- → Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers(2018)430 cited
- → MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis(2016)424 cited
- → Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats(2008)417 cited
- → Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations(2018)278 cited